Expand all sections

Exoflo Extracellular Vesicles

Extended indication Exoflo extracellular vesicles monotherapy for treatment of moderate to severe Acute respiratory dist
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Exoflo Extracellular Vesicles
Domain Lung diseases
Reason of inclusion New medicine (specialité)
Extended indication Exoflo extracellular vesicles monotherapy for treatment of moderate to severe Acute respiratory distress syndrome in hospitalized adults and elderly
Manufacturer Direct Biologics
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date June 2025
Expected Registration July 2026
Orphan drug No
Registration phase Clinical trials
Additional remarks NCT05354141

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.